• Vaccine Name: rB/HPIV3- RSV-F
• Target Pathogen: Human Respiratory Syncytial Virus
• Target Disease: Respiratory tract disease
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• F protein gene engineering:
  • Type: Recombinant vector construction
  • Description: RSV F from the first (pre-N), second (N-P), third (P-M), and sixth (HN-L) genome positions is expressed in a recombinant vaccine vector rB/HPIV3 viruses (Liang et al., 2014).
  • Detailed Gene Information: Click Here.
• Preparation: rB/HPIV3 viruses expressing RSV F from the first (pre-N), second (N-P), third (P-M), and sixth (HN-L) genome positions (Liang et al., 2014),
• Immunization Route: Intramuscular injection (i.m.)

Hamster Response

• Vaccination Protocol: The hamsters were inoculated intranasally with 0.1 ml containing 10^6 TCID50 of rB/HPIV3-RSV F virus or with 10*6 PFU of wt RSV (A2 strain) (Liang et al., 2014) .
• Challenge Protocol: Challenge was performed by intranasal infection with 106 PFU of RSV in 0.1 ml at 31 days after immunization(Liang et al., 2014)
• Efficacy: Each rB/HPIV3 vector induced a high titer of neutralizing antibodies in hamsters against RSV and HPIV3. Protection against RSV challenge was greater for position 2 than for position 6. Evaluation of insert stability suggested that RSV F is under selective pressure to be silenced during vector replication in vivo, but this was not exacerbated by a high level of RSV F expression and generally involved a small percentage of recovered vector (Liang et al., 2014)